• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Vicept Therapeutics

edit

Viceptâ„¢ (Vicept Therapeutics, Inc.), based in Malvern, Pennsylvania, is a privately held specialty biopharmaceutical company founded in August, 2009 with a mission to develop the first effective topically applied-therapy directed toward the erythema (skin redness) of rosacea and other dermatologic disorders characterized by redness and or ‘flushing’ of the skin.

Recent Milestones

edit

• 
  Vicept Therapeutics was acquired by Allergan for $275M. (7/19/11)
  Posted 7/19/11 at 10:46pm via fiercebiotech.com
• 
  Vicept Therapeutics received $16M in Series A funding. (6/30/10)
  Posted 6/30/10 at 6:15pm via vicepttx.com
• 
  Vicept Therapeutics added Christopher Powala as COO.
  Posted 6/30/10 at 6:15pm
• 
  Vicept Therapeutics added Neal Walker as Director, President & CEO.
  Posted 6/30/10 at 6:15pm
• 
  Vicept Therapeutics added Frank Ruffo as CFO.
  Posted 6/30/10 at 6:15pm
• 
  Vicept Therapeutics added Stuart D. Shanler as CSO.
  Posted 7/1/10 at 8:00am

Videos

Screenshots

edit

Sources

1. Allergan scoops up fledgling Vicept in $275M buyout pact (fiercebiotech.com) [edit]
2. Vicept Therapeutics Secures $10 Million to Complete Series A Funding (vicepttx.com) [edit]